Reju Therapeutics, the first biotech company in China targeting aging biology, announced the completion of an oversubscribed Series A financing round of hundreds of millions of RMB. The round was jointly invested by Cathay Capital, Fosun Health Capital, Efund Capital, and Nanjing Huatai GenScript Biotech Venture Capital LP. Proceeds will accelerate the company’s clinical‑stage innovative drug pipelines, expand the pipeline layout of its core technology platform, and continuously strengthen its fully integrated innovation ecosystem spanning anti‑aging mechanism research, drug R&D, and clinical translation.
Financing Snapshot
| Item | Detail |
|---|---|
| Company | Reju Therapeutics (private) |
| Round | Series A – oversubscribed |
| Amount | Hundreds of millions of RMB (exact figure not disclosed) |
| Announcement Date | 21 Oct 2026 |
| Investors | Cathay Capital, Fosun Health Capital, Efund Capital, Nanjing Huatai GenScript Biotech Venture Capital LP |
| Use of Proceeds | Accelerate clinical‑stage innovative drug pipelines; expand core technology platform pipeline layout; strengthen integrated anti‑aging innovation ecosystem |
| Valuation / Post‑Money Terms | Not disclosed |
Company Profile & Core Platform
- Category Pioneer: First biotech company in China focused on aging biology, dedicated to the development of “Senotherapeutics” – therapies for aging‑related diseases.
- Fully Integrated Ecosystem: An end‑to‑end innovation chain covering anti‑aging mechanism research, drug R&D, and clinical translation, positioning the company across the full value cycle of longevity medicine.
- Platform Expansion: Series A proceeds will fund further pipeline layout on the core technology platform, broadening coverage of aging‑related indications (specific platform modalities not disclosed).
- Clinical Stage: The company has advanced to clinical‑stage development, with capital earmarked to accelerate ongoing programs.
Regulatory Milestone – Dual NMPA/FDA IND Clearances
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA, China) and U.S. Food and Drug Administration (FDA) |
| Milestone | Investigational New Drug (IND) approvals |
| Timing | March 2026 |
| Scope | Two core pipelines cleared concurrently by both NMPA and FDA |
| Significance | First anti‑aging innovative drug candidate from China cleared by the FDA to enter clinical trials |
| Pipeline Names / Indications | Not disclosed |
In March 2026, two core Reju pipelines concurrently received IND approvals from both the NMPA and the FDA – making Reju the owner of the first anti‑aging innovative drug candidate from China to be cleared by the FDA for clinical investigation, a landmark for Chinese longevity biotech on the global regulatory stage.
Market Impact & Outlook
- Longevity Medicine Momentum: Aging biology and senotherapeutics represent one of the fastest‑emerging frontiers in global biotech, as aging populations drive demand for therapies addressing the root mechanisms of aging‑related diseases.
- Investor Validation: An oversubscribed round co‑led by Cathay Capital, Fosun Health Capital, Efund Capital, and Nanjing Huatai GenScript Biotech Venture Capital LP signals strong institutional conviction in Reju’s platform and dual‑jurisdiction clinical strategy.
- China–U.S. Dual Track: Concurrent NMPA and FDA IND clearances enable parallel clinical development in the world’s two largest pharmaceutical markets, a rare capability for a China‑originated anti‑aging company.
- Next Steps: Deployment of Series A capital into clinical‑stage acceleration and platform expansion; clinical trial designs, target indications, and follow‑on financing plans were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Reju Therapeutics’ use of Series A proceeds, clinical development timelines, pipeline expansion, and commercial potential of its senotherapeutics programs. Actual results may differ materially due to risks including clinical trial outcomes, regulatory review in China and the United States, competitive dynamics in the aging‑biology field, and the availability of future financing.-Fineline Info & Tech
